Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) have been assigned a consensus rating of "Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $402.1429.
A number of research firms recently issued reports on ONC. Royal Bank Of Canada dropped their price target on shares of BeOne Medicines from $451.00 to $450.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Citizens Jmp upped their price objective on shares of BeOne Medicines from $396.00 to $405.00 and gave the stock a "market outperform" rating in a research report on Thursday, August 6th. Morgan Stanley reaffirmed an "overweight" rating on shares of BeOne Medicines in a report on Thursday, August 6th. Finally, TD Cowen lifted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a "buy" rating in a research report on Thursday, August 6th.
Read Our Latest Report on ONC
Insiders Place Their Bets
In related news, CEO John Oyler sold 145,861 shares of the firm's stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95. Following the transaction, the chief executive officer directly owned 8,122 shares of the company's stock, valued at approximately $2,484,925.90. This trade represents a 94.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 588,481 shares of company stock valued at $192,918,836. Company insiders own 6.19% of the company's stock.
Hedge Funds Weigh In On BeOne Medicines
A number of hedge funds have recently made changes to their positions in ONC. EFG International AG acquired a new stake in shares of BeOne Medicines in the fourth quarter worth approximately $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines in the 4th quarter valued at $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines in the 2nd quarter valued at $35,000. CWM LLC lifted its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines during the 4th quarter worth $61,000. Institutional investors and hedge funds own 48.55% of the company's stock.
BeOne Medicines Stock Performance
NASDAQ ONC opened at $358.26 on Friday. The stock has a market capitalization of $39.33 billion, a price-to-earnings ratio of 63.07 and a beta of 0.51. The stock has a 50-day moving average of $333.94 and a 200 day moving average of $311.69. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines has a twelve month low of $253.95 and a twelve month high of $385.22.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.40 by $0.65. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Sell-side analysts anticipate that BeOne Medicines will post 8.81 EPS for the current fiscal year.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
